Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation.
Unterrainer M, Deroose CM, Herrmann K, Moehler M, Blomqvist L, Cannella R, Caramella C, Caruso D, Chouhan MD, Denecke T, De la Pinta C, De Geus-Oei LF, Dulskas A, Eisenblätter M, Foley KG, Gourtsoyianni S, Lecouvet FE, Lopci E, Maas M, Obmann MM, Oprea-Lager DE, Verhoeff JJC, Santiago I, Terraz S, D'Anastasi M, Regge D, Laghi A, Beets-Tan RGH, Heinemann V, Lordick F, Smyth EC, Ricke J, Kunz WG; European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group. Electronic address: https://twitter.com/@EORTC; European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group; European Society of Oncologic Imaging (ESOI) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). Unterrainer M, et al. Among authors: kunz wg. Eur J Cancer. 2022 Nov;176:193-206. doi: 10.1016/j.ejca.2022.09.012. Epub 2022 Sep 28. Eur J Cancer. 2022. PMID: 36274570 Free article.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: kunz wg. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, Wardelmann E, Hofer S; Writing committee on behalf of CSSS panellists. Rothermundt C, et al. Among authors: kunz wg. Eur J Cancer. 2023 Feb;180:158-179. doi: 10.1016/j.ejca.2022.11.008. Epub 2022 Nov 16. Eur J Cancer. 2023. PMID: 36599184 Free article.
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: kunz wg. Cytotherapy. 2023 Sep;25(9):986-992. doi: 10.1016/j.jcyt.2023.03.007. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055322
Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE.
Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, Beyer L, Brendel M, Kunz WG, Winkelmann M, Cyran CC, Ricke J, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Belka C, Niyazi M, Tonn JC, Bartenstein P, Albert NL. Unterrainer M, et al. Among authors: kunz wg. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3390-3399. doi: 10.1007/s00259-023-06315-z. Epub 2023 Jun 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37358620 Free PMC article.
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Holzgreve A, et al. Among authors: kunz wg. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3750-3754. doi: 10.1007/s00259-023-06332-y. Epub 2023 Jul 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 37428216 Free PMC article.
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Pasquier D, et al. Lancet Oncol. 2023 Aug;24(8):e331-e343. doi: 10.1016/S1470-2045(23)00286-3. Lancet Oncol. 2023. PMID: 37541279 Review.
178 results